Bioaffinity Technologies, Inc. income statement

In fiscal 2025, Bioaffinity Technologies, Inc. reported revenue of $6.2m, down 34.2% on the year before, operating income of −$10.6m (a -171.6% margin) and net income of −$14.9m, or −$8.66 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bioaffinity Technologies, Inc.: income statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	7	8	9	6	6
Cost of revenue	0	—	—	—	—
Gross profit	0	—	—	—	—
Research and development	1	1	1	1	1
Selling, general and administrative	2	7	10	10	11
Operating income	−4	−8	−9	−11	−12
Interest expense	3	0	0	0	0
Income before tax	−8	−8	−9	−15	−15
Income tax	0	0	0	0	—
Net income	−8	−8	−9	−15	−15
Diluted EPS	−$27.15	−$0.91	−$22.50	−$8.66	—
Diluted shares (average)	—	—	—	2m	—
EBITDA	−4	−8	−8	−10	−12

US$ thousands unless shown otherwise. Fiscal quarters.

Bioaffinity Technologies, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	2,350	2,208	1,854	1,269	1,446	1,593	1,352	1,511
Research and development	274	391	367	311	331	374	350	362
Selling, general and administrative	2,365	2,920	2,453	2,215	2,209	3,037	3,242	2,859
Operating income	−1,974	−2,947	−2,627	−2,516	−2,293	−3,137	−3,617	−3,335
Interest expense	22	25	15	10	5	13	15	12
Income before tax	−1,998	−2,967	−2,652	−4,032	−5,048	−3,134	−3,631	−3,366
Income tax	3	0	9	29	3	3	—	—
Net income	−2,001	−2,967	−2,660	−4,061	−5,051	−3,137	−3,631	−3,366
Diluted EPS	−$4.84	−$6.28	−$4.80	−$5.07	−$4.74	−$1.11	−$0.81	−$0.64
EBITDA	−1,823	−2,793	−2,473	−2,402	−2,179	−3,013	−3,502	−3,273

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BIAF vs LUCD BIAF vs NRXS BIAF vs MCTA

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bioaffinity Technologies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioaffinity Technologies, Inc.